In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Neurogene (NGNE – Research Report), with a price target of $26.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Evan Seigerman has given his Buy rating due to a combination of factors that highlight the potential of Neurogene’s NGN-401 in treating Rett syndrome. The pivotal trial design for NGN-401 shows promise, as it aligns with FDA guidelines and does not require a matched placebo, allowing patients to serve as their own controls. This design is expected to demonstrate clear benefits for patients, with a primary endpoint that includes both a developmental milestone gain and a CGI-I score of 3 or better.
Neurogene’s trial strategy, which includes enrolling younger patients and a slightly larger cohort, could lead to a broader label if the results are positive. The early phase 1/2 trials have already validated the safety of the low dose, and preclinical studies support the functional activity and potential reversibility of Rett syndrome. The combination of these factors, along with the high unmet need for effective treatments, underpins Seigerman’s optimistic outlook for Neurogene’s stock.
In another report released today, Stifel Nicolaus also reiterated a Buy rating on the stock with a $46.00 price target.
NGNE’s price has also changed moderately for the past six months – from $22.280 to $14.950, which is a -32.90% drop .